Results 81 to 90 of about 4,121 (173)

Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis

Терапевтический архив, 2015
Aim. To study the clinical and laboratory efficiency and safety of different etoricoxib (ET) regimens in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. Subjects and methods.
I Z Gaydukova, A P Rebrov
doaj  

Erectile dysfunction in ankylosing spondylitis patients

International Brazilian Journal of Urology
Background Rheumatic diseases such as ankylosing spondylitis (AS) may be associated with sexual dysfunction. Aim To study erectile function of a group of Brazilian AS patients comparing them with controls.
Thiago Santana, Thelma Skare, Vitor Steil Delboni, Juliana Simione, Ana Paula B. Campos, Renato Nisihara   +5 more
doaj   +1 more source

Ethnicity and patient reported outcome BASDAI in the monitoring of axial spondyloarthropathy: Does it matter?

Musculoskeletal Care, 2022
Swetha Byravan, Sindhuja Jothimurugan, Arumugam Moorthy   +2 more
openaire   +2 more sources

Bone Mineral Density in Ankylosing Spondylitis

Türk Osteoporoz Dergisi, 2003
Ankylosing Spondylitis (AS), a chronic inflammatory rheumatic disease. One of the most frequent and important complications in these patients is osteoporosis.
Bahar Çakmak, Hidayet Sarı
doaj  

Interrelations of disease activity, health-related quality of life, and mental health in axial spondyloarthritis: the Rheuma-VOR cohort. [PDF]

Front Med (Lausanne)
Schiestl LJ, Wendt E, Proft F, Hoeper K, Witte T, Assmann G, Schwarting A, Dreher M.   +7 more
europepmc   +1 more source

Neurological Symptoms and Comorbidities in Patients with Ankylosing Spondylitis. [PDF]

J Clin Med
Köse E, Sevim MS.
europepmc   +1 more source

Correlation between BASDAI and ASDAS to evaluate the activity of patients with spondyloarthritis [PDF]

, 2018
Saadia Ait malek, Sara El Rharras, Ahmed Mougui, Houda Sahraoui, Imane El Bouchti   +4 more
openaire   +1 more source

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. [PDF]

RMD Open
Navarro-Compán V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H.   +9 more
europepmc   +1 more source

The CALLY Index May Reflect Systemic Inflammatory Burden Rather than Patient-Reported Disease Activity in Ankylosing Spondylitis: A Medical Record-Based Cross-Sectional Study. [PDF]

J Clin Med
Güner A, Dandinoğlu T, Güner ST, Aykurt Karlıbel İ.   +3 more
europepmc   +1 more source

Validation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis. [PDF]

Rheumatol Int
Ozoglu M, Temiz Karadag D, Gokcen N, Ozdemir Isik O, Yilmaz H, Cefle A, Yazici A.   +6 more
europepmc   +1 more source